Changmeng Cai

15PUBLICATIONS
45CO-AUTHORS
Genome structure and regulationMolecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Cancer cell biology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Sep 09, 2026
Minimal-length CAG repeats in AR define a hyperactive AR-LSD1 axis driving metabolic reprogramming in prostate cancer.

|Jun 23, 2026
Identification of targets of clinical FOXA1 mutants involved in EMT and immune suppression in prostate cancer.

|May 01, 2026
Single-cell imaging analysis, therapeutic modeling and a Phase Ib trial validate BCL-2 as a target across heterogeneous castration-resistant prostate cancer.

|Mar 21, 2025
Heterogeneous Responses to High-Dose Testosterone in Castration-Resistant Prostate Cancer Tumors with Mixed Rb-Proficient and Rb-Deficient Cells.

Maryam Labaf, Wanting Han, Songqi Zhang

|Oct 28, 2024
Voluntary Exercise Attenuates Tumor Growth in a Preclinical Model of Castration-Resistant Prostate Cancer.

Nicolas Berger, Benjamin Kugler, Dong Han

|Jun 08, 2024
FOXA2 rewires AP-1 for transcriptional reprogramming and lineage plasticity in prostate cancer.

Zifeng Wang, Scott L Townley, Songqi Zhang

Pageof 3

Frequent Collaborators

9 joint publications

Shuai Gao

8 joint publications

Jill A Macoska

7 joint publications

Wanting Han

7 joint publications

Housheng Hansen He